دورية أكاديمية

Clinical grade production of IL‐15 stimulated NK cells for early infusion in adult AML patients undergoing haploidentical stem cell transplantation with post‐transplant cyclophosphamide.

التفاصيل البيبلوغرافية
العنوان: Clinical grade production of IL‐15 stimulated NK cells for early infusion in adult AML patients undergoing haploidentical stem cell transplantation with post‐transplant cyclophosphamide.
المؤلفون: Rubio‐Azpeitia, Eva, Pérez‐Corral, Ana Maria, Dorado‐Herrero, Nieves, Monsalvo, Silvia, Pérez‐Balsera, Gonzalo, Fernández‐Santos, Maria Eugenia, Kwon, Mi, Oarbeascoa, Gillen, Bastos‐Oreiro, Mariana, Falero, Carmen, Pascual Izquierdo, Cristina, Muñoz‐Martínez, Cristina, Pérez‐Martínez, Antonio, Diez‐Martin, José Luis, Anguita, Javier
المصدر: Transfusion; Feb2022, Vol. 62 Issue 2, p374-385, 12p
مصطلحات موضوعية: HEMATOPOIETIC stem cell transplantation, STEM cell transplantation, KILLER cells, ACUTE myeloid leukemia, CYCLOPHOSPHAMIDE
مستخلص: Background: Allogeneic stem cell transplantation is the treatment of choice for acute myeloid leukemia (AML) patients. Unmanipulated haploidentical transplantation (Haplo‐HSCT) is commonly used for those AML patients who need a timely transplant and do not have a suitable matched donor, but relapse rates are still high, and improvements are needed. Adoptive immunotherapy using natural killer cells (NK cells) could be a promising tool to improved Haplo‐HSCT but, to date, no optimal infusion and manufacturing protocols have been developed. Study Design and Methods: In this study, we describe a quick and reproducible protocol for clinical‐grade production of haploidentical donor NK cells using double immunomagnetic depletion and enrichment protocol and overnight IL‐15 stimulation. Results: Thus, we have obtained 8 viable and functional NK cell products that have been safely infused to five AML patients undergoing unmanipulated Haplo‐HSCT. Discussion: Our results demonstrate the safety and feasibility of manufactured NK IL15 cells obtained from an adult allogeneic donor in the setting of haploidentical transplantation for AML patients. [ABSTRACT FROM AUTHOR]
Copyright of Transfusion is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:00411132
DOI:10.1111/trf.16790